---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-23-000154"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T13:13:09.815121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%

## Summary
- Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).
- Base business revenue $2.27B (+4.6% YoY); COVID-19 testing revenue $26M (down 92% YoY).
- FY2023 guidance: revenue $9.19B-$9.24B, adjusted EPS $8.65-$8.75, raised low end from prior.
- Successfully negotiated all strategic health plan renewals for 2023; cites strong physician/hospital channels.
- Operating cash flow $207M in Q3 vs $502M year ago; capex $105M.

## SEC filing metadata
- accession: 0001022079-23-000154
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/dgx-20231024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-23-000154
- JSON: https://secwatch.observer/filing/0001022079-23-000154.json
- Plain text: https://secwatch.observer/filing/0001022079-23-000154.txt

## Key facts
- Earnings Releases
  QUEST DIAGNOSTICS INC reported the quarter ended September 30, 2023 results: revenue $2,295, net income $225, EPS $1.96.
  - Period: the quarter ended September 30, 2023
  - Revenue: $2,295
  - Net income: $225
  - EPS: $1.96
  - Result: reported results
  source text: growth.” Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Change 2023 2022 Change (dollars in millions, except per share data) Reported: Net revenues $ 2,295 $ 2,486 (7.7) % $ 6,964 $ 7,550 (7.8) % Base business revenues (a) $ 2,269 $ 2,170 4.6 % $ 6,778 $ 6,280 7.9 % COVID-19 testing revenues $ 26 $ 316 (92.0) % $ 186 $ 1,270 (85.4) %
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm
- Earnings Releases
  QUEST DIAGNOSTICS INC updated its Full Year 2023 guidance (reaffirmed).
  - Period: Full Year 2023
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The company updates its Full Year 2023 guidance as follows: Updated Guidance Prior Guidance Low High Low High Net revenues $9.19 billion $9.24 billion $9.12 billion $9.22 billion Net revenues decrease (7.0)% (6.5)% (7.7)% (6.7)% Base business revenues (a) $8.99 billion $9.04 billion $8.92 billion $9.02 billion Base business revenues increase 6.7% 7.3% 5.8% 7.0% COVID-19 testing revenues Approximately $200 million Approximately $200 million COVID-19 testing revenues decrease (86.2)% (86.2)% Reported diluted EPS $7.61 $7.71 $7.52 $7.92 Adjusted diluted EPS $8.65 $8.75 $8.50 $8.90 Cash provided by operations Approximately $1.3 billion At least $1.3 billion Capital expenditures Approximately $400 million Approximately $400 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.